Connor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Connor Clark & Lunn Investment Management increased its Johnson & Johnson stake by 9.2% in Q3, buying 16,054 shares to hold 189,990 shares worth about $35.23 million per its SEC filing.
• Johnson & Johnson reported $2.46 EPS for the quarter, has a market cap of $584.2 billion and a P/E of 21.94, and pays a quarterly dividend of $1.30 (annualized $5.20) for a ~2.1% yield with a 47.06% payout ratio.
• Positive catalysts include FDA approval of the TECNIS PureSee intraocular lens and several analyst price-target raises (e.g., Citigroup to $274, BofA to $253), while the consensus rating remains a "Moderate Buy" with a $235.91 target.

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 189,990 shares of the company's stock after buying an additional 16,054 shares during the period. Connor Clark & Lunn Investment Management Ltd.'s holdings in Johnson & Johnson were worth $35,228,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Abich Financial Wealth Management LLC bought a new stake in Johnson & Johnson in the third quarter worth $26,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the third quarter valued at $28,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $27,000. Semmax Financial Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc boosted its stake in shares of Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company's stock worth $42,000 after purchasing an additional 198 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $242.43 on Friday. The company has a market capitalization of $584.24 billion, a P/E ratio of 21.94, a P/E/G ratio of 2.40 and a beta of 0.34. The company's 50-day simple moving average is $231.22 and its two-hundred day simple moving average is $205.79. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson's dividend payout ratio (DPR) is currently 47.06%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on JNJ shares. Bank of America reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Scotiabank restated an "outperform" rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Daiwa Securities Group upped their target price on Johnson & Johnson from $203.00 to $237.00 and gave the company an "outperform" rating in a research note on Thursday, January 29th. Leerink Partners increased their price target on Johnson & Johnson from $201.00 to $232.00 and gave the stock a "market perform" rating in a report on Thursday, January 22nd. Finally, Weiss Ratings restated a "buy (b)" rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $235.91.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the TECNIS PureSee intraocular lens for U.S. cataract patients — a commercial win for J&J’s Vision franchise that could drive incremental device sales and strengthen the company’s near-term revenue mix. Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens
• Positive Sentiment: Citigroup raised its price target to $274 and placed a Buy rating — a bullish analyst call that signals meaningful upside versus the current share level and may attract buyers. Benzinga
• Positive Sentiment: BofA increased its price target to $253 (from $227) citing pipeline growth while keeping a Neutral rating — the higher target and raised revenue assumptions reflect improving visibility on key drugs and support medium-term upside. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: JNJ requested an EU label expansion for multiple myeloma drug Tecvayli based on phase III MajesTEC-9 data — approval would broaden indicated use and market opportunity in oncology. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Analyst commentary (Zacks) highlights J&J among names with strong business momentum despite macro headwinds — supportive narrative for investor confidence. The Zacks Analyst Blog: JPMorgan, Johnson & Johnson, Applied Materials and Value Line
• Neutral Sentiment: Coverage/narrative updates show modest fair‑value adjustments (e.g., fair value moved slightly to ~$237) as analysts rework individual drug assumptions — incremental but not game‑changing. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
• Neutral Sentiment: Barclays reaffirmed a Hold rating — keeps a portion of sell‑side sentiment cautious despite positive pipeline headlines. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: J&J appears on lists of “safe” dividend aristocrats — supportive for income investors but unlikely to trigger large near‑term moves. Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats

Insider Activity

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the firm's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. This trade represents a 4.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 30,142 shares of company stock valued at $7,360,528 over the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.